SciTech Development Inc. - Pioneering Cancer Treatment with Nanotechnology
SciTech Development Inc. was originally formed from the collaborative efforts between Karmanos Cancer Institute and Wayne State University. With innovative science and advanced nanotechnology, SciTech has developed ST-001 nanoFenretinide, a patented new drug with clinical trials in progress for T-cell lymphoma (a form of non-Hodgkin lymphoma) as its gateway indication. Click here to learn more about the SciTech story.
About ST-001 - Fenretinide, the active pharmaceutical ingredient (API) in ST-001, has been widely studied and known for its potential in treating various cancers. However, the drug faced a critical challenge: poor absorption by the human body meant that the drug could not reach cancer cells in sufficient quantities to be effectively therapeutic. The SciTech team solved this problem by utilizing its proprietary SciTech Drug Delivery Platform (SDP) that encapsulates fenretinide in nanoparticles. This breakthrough allows the drug to bypass traditional absorption barriers, delivering higher concentrations of the drug directly to cancer cells without the toxic side effects that often plague other therapies, such as chemotherapy. Click here to learn how ST-001 kills cancer cells.
Clinical Trials are Underway - SciTech is halfway through the accelerated portion of the Phase 1a clinical trial for T-cell non-Hodgkin lymphoma (T-NHL) and plans to advance into Phase 1b in the second quarter of 2025. Concurrently, the company is preparing for trials in small-cell lung cancer, expanding its therapeutic reach.
Leadership and Vision - Under the stewardship of Earle Holsapple, a seasoned industry leader, SciTech's team of experts are committed to rapid clinical trial strategies aimed at swiftly bringing ST-001 to market. This leadership has already steered the company through significant milestones, including raising over $12 million in funding and showcasing strong investor confidence.
Why Invest Now?
-
Innovation: SciTech is at the cutting edge of cancer drug delivery with a technology that could redefine treatment protocols in various cancers.
-
Market Potential: The demand for less toxic, more effective cancer treatments are undeniable, offering a vast market for ST-001 in multiple indications.
-
Strategic Growth: With a clear roadmap from clinical trials to commercialization, SciTech is on a path that could lead to significant returns.
-
Social Impact: Investing in SciTech means contributing to a future where cancer treatments are more humane and effective, potentially saving countless lives.
Join the Revolution!
As SciTech advances towards its next clinical milestones, the opportunity to invest in this game-changing company is now. Be part of a legacy that could alter the landscape of cancer treatment.
CONTACT INFORMATION
David R. Schaffer
Director, Investor Relations and Business Development
+1 (727) 278-8118